STAAR Surgical (NASDAQ:STAA) VP Jon K. Hayashida sold 2,813 shares of the firm’s stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $26.83, for a total transaction of $75,472.79. Following the completion of the transaction, the vice president now owns 13,607 shares in the company, valued at approximately $365,075.81. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
NASDAQ:STAA opened at $32.82 on Friday. The stock has a market cap of $1.21 billion, a P/E ratio of 109.40 and a beta of 2.07. The firm’s fifty day simple moving average is $31.49 and its 200 day simple moving average is $32.99. STAAR Surgical has a twelve month low of $21.70 and a twelve month high of $42.73. The company has a quick ratio of 4.57, a current ratio of 5.07 and a debt-to-equity ratio of 0.03.
STAAR Surgical (NASDAQ:STAA) last released its quarterly earnings results on Wednesday, February 26th. The medical instruments supplier reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.09. The business had revenue of $38.88 million for the quarter, compared to analysts’ expectations of $39.10 million. STAAR Surgical had a net margin of 9.35% and a return on equity of 14.71%. During the same quarter in the previous year, the business posted $0.02 earnings per share. On average, analysts expect that STAAR Surgical will post 0.48 EPS for the current fiscal year.
Several analysts recently weighed in on the stock. BTIG Research reiterated a “buy” rating and issued a $46.00 price target on shares of STAAR Surgical in a report on Tuesday, March 10th. Zacks Investment Research cut shares of STAAR Surgical from a “buy” rating to a “hold” rating in a report on Thursday, January 9th. ValuEngine cut shares of STAAR Surgical from a “buy” rating to a “hold” rating in a report on Tuesday, March 17th. BidaskClub upgraded shares of STAAR Surgical from a “sell” rating to a “hold” rating in a report on Thursday. Finally, Stephens cut their price target on shares of STAAR Surgical from $56.00 to $37.00 and set an “overweight” rating on the stock in a report on Monday. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $39.50.
A number of large investors have recently added to or reduced their stakes in STAA. Capital International Investors lifted its position in STAAR Surgical by 45.1% during the fourth quarter. Capital International Investors now owns 1,833,100 shares of the medical instruments supplier’s stock valued at $64,470,000 after buying an additional 569,400 shares during the period. Broadfin Capital LLC purchased a new position in STAAR Surgical during the fourth quarter valued at $16,253,000. Loomis Sayles & Co. L P purchased a new position in STAAR Surgical during the fourth quarter valued at $15,658,000. UBS Asset Management Americas Inc. lifted its position in STAAR Surgical by 1,349.2% during the fourth quarter. UBS Asset Management Americas Inc. now owns 372,043 shares of the medical instruments supplier’s stock valued at $13,085,000 after buying an additional 346,370 shares during the period. Finally, Jericho Capital Asset Management L.P. purchased a new position in STAAR Surgical during the third quarter valued at $5,413,000. Institutional investors and hedge funds own 93.83% of the company’s stock.
STAAR Surgical Company Profile
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.
See Also: Gap Up Stocks
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.